演題

StageⅢb大腸癌における予後因子としてのCEAの有用性

[演者] 寺石 文則:1
[著者] 坂本 真樹:1, 高田 暢夫:1, 土居 大介:1, 谷岡 信寿:1, 尾崎 和秀:1, 志摩 泰生:1, 中村 敏夫:1, 福井 康雄:1, 西岡 豊:1
1:高知医療センター 外科

Purpose:The aim of this study was to evaluate the prognostic impact of preoperative serum CEA level in patients with StageIIIb colorectal cancer. Methods:A retrospective review was conducted on fifty-three patients who underwent curative resection for StageIIIb colorectal cancer from January 2010 to December 2014. Patient demographics, operative details, and surgical outcome were analyzed. Results:Based on TNM classification, StageIIIA, StageIIIB, and StageIIIC were identified in one, 28, and 24 patients, respectively. At a median follow-up of 35 months, the 3-year estimated overall survival (OS) and relapse-free survival (RFS) of all patients were 64.8 and 51.9 %, respectively. The 3-year OS of patients with StageIIIA/IIIB, and StageIIIC were 78.7% and 46.8%, respectively (P< 0.01). Analysis of survival revealed a significant worse 3-year OS of elevated-CEA level (> 5ng/mL) patients (26.7%) compared with that of the normal CEA level patients (65.6%) with StageIIIC colorectal cancer (P< 0.05). The 3-year RFS of the patients with elevated preoperative CEA and normal CEA was 0% and 44.4%, respectively (P< 0.01).Conclusions: Our results suggest that an elevated preoperative CEA level is strong predictor of recurrence and poor prognosis for StageIIIC colorectal cancer after radical surgery.
詳細検索